With 0.56 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.31 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $1.6796 whereas the lowest price it dropped to was $1.55. The 52-week range on MIRA shows that it touched its highest point at $2.56 and its lowest point at $0.73 during that stretch. It currently has a 1-year price target of $17.75. Beta for the stock currently stands at 1.76.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MIRA was up-trending over the past week, with a rise of 20.29%, but this was up by 12.93% over a month. Three-month performance surged to 37.19% while six-month performance rose 66.00%. The stock gained 45.61% in the past year, while it has gained 13.70% so far this year. A look at the trailing 12-month EPS for MIRA yields -0.48 with Next year EPS estimates of -0.10. For the next quarter, that number is -0.10. This implies an EPS growth rate of 29.52% for this year and 74.32% for next year.
Float and Shares Shorts:
At present, 17.39 million MIRA shares are outstanding with a float of 14.26 million shares on hand for trading. On 2025-08-29, short shares totaled 0.21 million, which was 111.00000000000001 higher than short shares on 1753920000. In addition to Mr. Erez Aminov as the firm’s CEO & Chairman, Mr. Alan Weichselbaum CPA, M.B.A. serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, MIRA reported revenue of $0.0 and operating income of -$1546100.0. The EBITDA in the recently reported quarter was -$1546100.0 and diluted EPS was -$0.09.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With MIRA analysts setting a high price target of 17.75 and a low target of 17.75, the average target price over the next 12 months is 17.75. Based on these targets, MIRA could surge 969.28% to reach the target high and rise by 969.28% to reach the target low. Reaching the average price target will result in a growth of 969.28% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.55333 being high and -$0.55333 being low. For MIRA, this leads to a yearly average estimate of -$0.55333. The surprise factor in the prior quarter was -$0.14. Based on analyst estimates, the high estimate for the next quarter is -$0.05 and the low estimate is -$0.05. The average estimate for the next quarter is thus -$0.05.
